Bristol-Myers Squibb New York City

News

Bristol Myers Squibb tops quarterly estimates, hikes Outlook

Bristol Myers Squibb tops quarterly estimates, hikes outlook as drugmaker braces for tariffs

The guidance revisions include the estimated impact of current tariffs on U.S. products shipped to China, but not Trump’s planned pharmaceutical tariffs.

Reuters · 3d

Bristol Myers posts higher-than-expected quarterly revenue on cancer drug sales

Bristol Myers Squibb reported higher-than-expected first-quarter revenue on Thursday and raised its full-year forecast due to growth from its portfolio of drugs that spur a patient's immune system to fight cancer.

Barron's on MSN · 3d

Bristol Myers Squibb Posts Better-than-Expected Earnings, Raises Full-Year Guidance

Bristol Myers Squibb reported better-than-expected earnings for the first quarter and boosted its outlook while noting the impact of stiff competition in the pharmaceutical market. Adjusted earnings of $1.

Seeking Alpha3d

Bristol-Myers gains as forex tailwinds prompt guidance raise

Shares of Bristol-Myers Squibb (NYSE:BMY) traded higher in the ... while the company’s new schizophrenia drug Cobenfy generated $27M in sales. “Our strong execution in the first quarter ...

Yahoo Finance5d

Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term

New York-based Bristol-Myers Squibb is one of the leading global specialty biopharmaceutical companies focused on developing treatments targeting severe diseases. Blockbuster immuno-oncology ...

13d

Bristol Myers says Phase 3 ODYSSEY-HCM Camzyos trial did not meet endpoints

Squibb “announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos for the treatment of adult patients with symptomatic New ...

Nasdaq12d

Bristol Myers' Heart Disease Drug Fails To Meet Primary Endpoints In Phase 3 Trial

(RTTNews) - Bristol Myers Squibb (BMY) announced that the Phase 3 ODYSSEY-HCM trial, which evaluated Camzyos or mavacamten for the treatment of adult patients with symptomatic New York Heart ...

13d

Bristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM Trial

Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the treatment of adult patients with symptomatic New York Heart Association (NYHA) ...

Medical Dialogues11d

Bristol Myers Squibb heart disease drug fails to meet main goals in late-stage study

Princeton: Bristol Myers Squibb has announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the treatment ...

Business Insider5d

Bristol-Myers Squibb (BMY) Has a New Rating from Cantor Fitzgerald

Bristol-Myers Squibb (BMY – Research Report) received a Hold rating and a $55.00 price target from Cantor Fitzgerald analyst Olivia Brayer yesterday. The company’s shares closed yesterday at ...

12d

Why US Pharma Giant Bristol Myers Squibb Stock Trading Lower On Tuesday?

Bristol Myers' Camzyos missed goals in a Phase 3 nHCM trial, showing no significant benefits over placebo but raised no new ...

Medical Dialogues10d

Mavacamten Misses Primary Endpoints in Phase 3 Trial for Non-Obstructive HCM

Bristol Myers Squibb announced that mavacamten did not achieve statistical significance in meeting the dual primary endpoints ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results